Akinfenwa et al., 2021 - Google Patents
Preventive administration of non-allergenic Bet v 1 peptides reduces allergic sensitization to major birch pollen allergen, Bet v 1Akinfenwa et al., 2021
View HTML- Document ID
- 469873655684983970
- Author
- Akinfenwa O
- Huang H
- Linhart B
- Focke-Tejkl M
- Vrtala S
- Poroshina A
- Nikonova A
- Khaitov M
- Campion N
- Eckl-Dorna J
- Niederberger-Leppin V
- Kratzer B
- Tauber P
- Pickl W
- Kundi M
- Campana R
- Valenta R
- Publication year
- Publication venue
- Frontiers in Immunology
External Links
Snippet
IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 17 kDa protein is the major allergen in birch pollen responsible for allergic rhinoconjunctivitis and asthma in birch pollen allergic patients. Allergen-specific …
- 102000004196 processed proteins & peptides 0 title abstract description 160
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eiwegger et al. | Recent developments and highlights in food allergy | |
| Dorofeeva et al. | Past, present, and future of allergen immunotherapy vaccines | |
| Zhernov et al. | Recombinant allergens for immunotherapy: state of the art | |
| Valenta et al. | Allergen‐specific immunotherapy: from therapeutic vaccines to prophylactic approaches | |
| Grönlund et al. | The major cat allergen, Fel d 1, in diagnosis and therapy | |
| Worm et al. | Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy | |
| Zuidmeer-Jongejan et al. | Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy | |
| Moldaver et al. | Immunotherapy with peptides | |
| Machado et al. | Fold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen | |
| Curin et al. | Next-generation of allergen-specific immunotherapies: molecular approaches | |
| O’Hehir et al. | T cell epitope peptide therapy for allergic diseases | |
| Akinfenwa et al. | Preventive administration of non-allergenic Bet v 1 peptides reduces allergic sensitization to major birch pollen allergen, Bet v 1 | |
| ES2353360T3 (en) | PEPTID COMBINATIONS FOR VACCINES AGAINST ALLERGY TO CATS. | |
| Diavatopoulos et al. | What is wrong with pertussis vaccine immunity? Why immunological memory to pertussis is failing | |
| Boyce et al. | Advances in mechanisms of asthma, allergy, and immunology in 2011 | |
| KR20100068252A (en) | Peptides for vaccine | |
| JP2015521467A (en) | Nucleic acids for allergy treatment | |
| US10919945B2 (en) | Modular antigen transportation molecules and uses therof | |
| Linhart et al. | Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy | |
| Rauber et al. | Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10-and IL-5-secreting T cells | |
| Otsu et al. | Peanut allergy: an evolving clinical challenge | |
| JP2016166194A (en) | Peptides for vaccine against birch allergy | |
| Pichler et al. | Allergen hybrids–next generation vaccines for F agales pollen immunotherapy | |
| Gómez-Casado et al. | Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines | |
| Rodriguez et al. | Immunotherapy with native molecule rather than hypoallergenic variant of Pru p 3, the major peach allergen, shows beneficial effects in mice |